Skip to main content
Clinical Trials/CTRI/2019/08/020765
CTRI/2019/08/020765
Completed
Phase 3

A RANDOMIZED CONTROLLED TRIAL ON THERAPEUTIC EFFICACY OF SIDDHA HERBAL FORMULATIONAAVARAI KIRUTHAMIN THE TREATMENT OF MADHUMEGA AVATHAIGAL(VII)-DIABETIC PERIPHERAL NEUROPATHY COMPLICATION OF NON-INSULIN DEPENDENT(TYPE-II)DIABETES MELLITUS - MADHUMEGAM

AYOTHIDOSS PANDITHAR HOSPITA0 sites60 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: E084- Diabetes mellitus due to underlying condition with neurological complications
Sponsor
AYOTHIDOSS PANDITHAR HOSPITA
Enrollment
60
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 12, 2020
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
AYOTHIDOSS PANDITHAR HOSPITA

Eligibility Criteria

Inclusion Criteria

  • BLOOD SUGAR FASTING \>126 mg/dl and \>200,post prandial blood sugar \>200 and \<350 mg/dl,GLYCATED HAEMOGLOBIN \> 7% AND \< 11%,DIABETES PERIPHERAL NEUROPATHY MADHUMEGA AVATHAIGAL,PATIENT WHO IS ALREADY UNDER SIDDHA MEDICATION FOR MADHUMEGAM,DIABETES WITH HYPERTENSION.

Exclusion Criteria

  • AGE BETWEEN 30 YEARS TO 65 YEARS BOTH GENDER,GLYCATED HAEMOGLOBIN \< 7% AND \> 11%,
  • INSULIN DEPENDENT DIABETES MELLITUS,SECONTARY DIABETES MELLITUS,PREGNANT WOMEN AND PLANNING TO BE PREGNANT WITHIN 3 MONTHS,GESTATIONAL DIABETES,EXISTING RENAL FAILURE INDICATED BY ELEVATED SERUM CREATININE LEVELS,CNS DISORDER CORONARY ARTERY DISEASE,THYROID DYSFUNCTION ,MALIGNANT AND ACCELERATED HYPERTENSIVE,SUBJECT THOSE WHO ARE NOT WILLING TO GIVING INFORMED CONCENT.

Outcomes

Primary Outcomes

Not specified

Similar Trials